electroCore, Inc. (ECOR)

Over the past six months, electroCore, Inc.'s stock has experienced several events and fluctuations. As of November 25, 2025, the stock price was $4.93, with a 52-week range between $4.16 and $19.49. While the stock has fallen by 56.94% over the last year and 2.20% in the last month, it has shown a 0.62% increase over the past six months. In Q2 2025, the company reported record quarterly revenue of $7.4 million, a 20% increase over Q2 2024, with year-to-date revenue reaching $14.1 million, up 22% compared to the first half of 2024, and a GAAP net loss of $3.7 million. The Annual General Meeting on September 2, 2025, reported EPS of -1.590 USD. In Q3 2025, electroCore announced net sales of $8.7 million, a 33% year-over-year increase, with a GAAP net loss of $3.4 million. In November 2025, the stock price fell below its 50-day and 15-day moving averages.

Information explicitly detailing demand seasonality for electroCore, Inc.'s products and services was not found in the provided search results. The company's revenue growth is linked to product innovation and market expansion, with the VA market being a primary driver. Given the nature of its products, which address conditions like migraine and cluster headaches, demand may be relatively stable rather than subject to strong seasonal fluctuations.

electroCore, Inc. is a bioelectronic medicine company specializing in non-invasive vagus nerve stimulation (nVNS) therapy, operating within the Health Technology sector. Its primary product is gammaCore, a prescription handheld device for treating pain associated with migraine and cluster headache. electroCore also offers non-prescription wellness products like Truvaga and acquired NeuroMetrix, adding products like Quell Fibromyalgia.

electroCore, Inc. has a geographic footprint that includes the United States, the United Kingdom, and other international markets. Key revenue channels include the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) systems, as well as the United Kingdom. In December 2020, the company expanded its international presence by entering into an exclusive distribution agreement with Pro Medical Baltic (PMB) for gammaCore in Eastern Europe, covering countries such as Lithuania, Latvia, Belarus, Kazakhstan, and Ukraine.

electroCore's brand reputation received a positive boost with its Truvaga™ Plus product being named “Best Relaxation Gadget” in Esquire's 2025 Sleep Awards.

electroCore, Inc. is owned by a combination of institutional shareholders and insiders. Institutional shareholders hold 9.11% of the company, while insiders hold 164.31%. Retail investors hold 0.00%. Joseph P. Errico is the largest individual shareholder, owning 48.30% of the company. Other major owners include Merck Global Health Innovation Fund LLC (41.85%), James L. L. Tullis (25.19%), and Thomas J. Errico (12.67%). Vanguard Group Inc is the largest institutional shareholder with 2.92% ownership. Insiders have bought shares in the past 3-12 months but have only sold shares in the past three months. Shareholders have also experienced dilution in the past year, with total shares outstanding increasing by 22%.